Items Tagged ‘daratumumab’

December 13, 2017

Addition of Darzalex™ Improves Outcomes in Newly Diagnosed Multiple Myeloma


The addition of Darzalex (daratumumab) to the standard treatment combination consisting of Velcade (bortezomib), melphalan, and prednisone (VMP) reduces disease progression or death by 50%, among patients with newly diagnosed multiple myeloma who are not eligible to undergo a stem cell transplant. These results were presented as a late-breaking abstract at the 2017 annual meeting […]

View full entry

Tags: bortezomib, daratumumab, Darzalex, melphalan, Multiple Myeloma, News, Precision Cancer Medicine, prednisone, velcade, VMP